{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:15:55Z","timestamp":1791490555143,"version":"4.3.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TFF Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allergic bronchopulmonary aspergillosis and invasive fungal diseases represent distinct infectious entities that cause significant morbidity and mortality. Currently, administered inhaled antifungal therapies are unapproved, have suboptimal efficacy, and are associated with considerable adverse reactions. The emergence of resistant pathogens is also a growing concern. Inhaled antifungal development programs are challenged by inadequate nonclinical infection models, highly heterogenous patient populations, low prevalence rates of fungal diseases, difficulties defining clinical trial enrollment criteria, and lack of robust clinical trial endpoints. On 25 September 2020, the US Food and Drug Administration (FDA) convened a workshop with experts in pulmonary medicine and infectious diseases from academia, industry, and other governmental agencies. Key discussion topics included regulatory incentives to facilitate development of inhaled antifungal drugs and combination inhalational devices, limitations of existing nonclinical models and clinical trial designs, patient perspectives, and industry insights.<\/jats:p>","DOI":"10.1093\/cid\/ciad607","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T02:44:26Z","timestamp":1696646666000},"page":"1564-1570","source":"Crossref","is-referenced-by-count":7,"title":["Food and Drug Administration Public Workshop Summary\u2014Addressing Challenges in Inhaled Antifungal Drug Development"],"prefix":"10.1093","volume":"78","author":[{"given":"Caroline J","family":"Jjingo","sequence":"first","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukal","family":"Bala","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Waack","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Needles","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Bensman","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"McMaster","sequence":"additional","affiliation":[{"name":"Division of Pharmacology\/Toxicology for Infectious Diseases, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blakely","sequence":"additional","affiliation":[{"name":"Division of ENT, Sleep, Respiratory, and Anesthesia, Office of Health Technology 1, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Z","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Medication Error Prevention and Analysis, Office of Medication Error Prevention and Risk Management, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Puthawala","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Allergy, and Critical Care, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Dixon","sequence":"additional","affiliation":[{"name":"Division of Biometrics IV, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongman","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Biometrics III, Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Allergy, and Critical Care, Office of Immunology and Inflammation, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Colangelo","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"St. Clair","sequence":"additional","affiliation":[{"name":"Division of Clinical Outcome Assessment, Office of Drug Evaluation Science, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumathi","family":"Nambiar","sequence":"additional","affiliation":[{"name":"Division of Anti-Infectives, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B","family":"Moss","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Lucile Packard Children's Hospital and Stanford Children's Health, Stanford University Medical Center , Palo Alto, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radu","family":"Botgros","sequence":"additional","affiliation":[{"name":"Office of Biological Health Threats and Vaccines Strategy, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bazaz","sequence":"additional","affiliation":[{"name":"National Aspergillosis Centre, University of Manchester , Manchester , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Denning","sequence":"additional","affiliation":[{"name":"Global Action Fund for Fungal Infections, The University of Manchester , Manchester , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren A","family":"Marr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases Clinic, University Health Network, University of Toronto , Toronto, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Berman","sequence":"additional","affiliation":[{"name":"Pulmocide , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale J","family":"Christensen","sequence":"additional","affiliation":[{"name":"TFF Pharmaceuticals , Fort Worth, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Keywood","sequence":"additional","affiliation":[{"name":"Zambon SpA , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell G","family":"Clayton","sequence":"additional","affiliation":[{"name":"Aeremedea LLC , Fenandina Beach, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Transplantation-Oncology Infectious Diseases Program, Weill Cornell Medicine , New York, New York , USA"},{"name":"Save Our Sick Kids Foundation , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Sook E","family":"Song","sequence":"additional","affiliation":[{"name":"DRT Strategies , Arlington, Virginia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita J","family":"Shukla","sequence":"additional","affiliation":[{"name":"Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Farley","sequence":"additional","affiliation":[{"name":"Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"2024061323543871400_ciad607-B1","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MCP.0000000000000129","article-title":"Allergic fungal airway disease: pathophysiologic and diagnostic considerations","volume":"21","author":"Woolnough","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"2024061323543871400_ciad607-B3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/hcm035","article-title":"Pulmonary aspergillosis: a clinical update","volume":"100","author":"Zmeili","year":"2007","journal-title":"QJM"},{"key":"2024061323543871400_ciad607-B4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"2024061323543871400_ciad607-B5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/13693786.2012.738312","article-title":"Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults","volume":"51","author":"Denning","year":"2013","journal-title":"Med Mycol"},{"key":"2024061323543871400_ciad607-B6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/myc.13213","article-title":"Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity","volume":"64","author":"Machado","year":"2021","journal-title":"Mycoses"},{"key":"2024061323543871400_ciad607-B7","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024061323543871400_ciad607-B8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fmb.12.28","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"7","author":"Shoham","year":"2012","journal-title":"Future Microbiol"},{"key":"2024061323543871400_ciad607-B9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1128\/CMR.18.1.44-69.2005","article-title":"Aspergillus infections in transplant recipients","volume":"18","author":"Singh","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2024061323543871400_ciad607-B10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00163511","article-title":"Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis","volume":"40","author":"Hilberg","year":"2012","journal-title":"Eur Respir J"},{"key":"2024061323543871400_ciad607-B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/jamp.2008.0715","article-title":"A review on the clinical use of inhaled amphotericin B","volume":"22","author":"Kuiper","year":"2009","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2024061323543871400_ciad607-B12","doi-asserted-by":"crossref","first-page":"2102218","DOI":"10.1183\/13993003.02218-2021","article-title":"Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial","volume":"59","author":"Godet","year":"2022","journal-title":"Eur Respir J"},{"key":"2024061323543871400_ciad607-B13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1345\/aph.1G477","article-title":"Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections","volume":"40","author":"Mohammad","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2024061323543871400_ciad607-B14","doi-asserted-by":"crossref","DOI":"10.1177\/1178636119869937","article-title":"Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease: an update","volume":"12","author":"Duckwall","year":"2019","journal-title":"Microbiol Insights"},{"key":"2024061323543871400_ciad607-B15","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/S2352-3026(22)00073-4","article-title":"Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: a systematic review and expert consensus recommendation from the European Hematology Association","volume":"9","author":"Stemler","year":"2022","journal-title":"Lancet Haematol"},{"key":"2024061323543871400_ciad607-B16","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","article-title":"Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation","volume":"40","author":"Borro","year":"2008","journal-title":"Transplant Proc"},{"key":"2024061323543871400_ciad607-B17","doi-asserted-by":"crossref","first-page":"9482","DOI":"10.1038\/s41598-019-45890-w","article-title":"Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection","volume":"9","author":"Colley","year":"2019","journal-title":"Sci Rep"},{"key":"2024061323543871400_ciad607-B18","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B19","author":"Organisation for Economic Co-operation and Development"},{"key":"2024061323543871400_ciad607-B20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1136\/thx.46.10.712","article-title":"Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique","volume":"46","author":"Newman","year":"1991","journal-title":"Thorax"},{"key":"2024061323543871400_ciad607-B21","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B22","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B23","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B24","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B25","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B26","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B27","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B28","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B29","author":"Food and Drug Administration"},{"key":"2024061323543871400_ciad607-B30","first-page":"559","article-title":"A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients","volume":"2","author":"Caillaud","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024061323543871400_ciad607-B31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N Engl J Med"},{"key":"2024061323543871400_ciad607-B32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.chest.2018.01.005","article-title":"A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"153","author":"Agarwal","year":"2018","journal-title":"Chest"},{"key":"2024061323543871400_ciad607-B33","first-page":"1","article-title":"Long-term effect of antifungal therapy for the treatment of severe resistant asthma: an active comparator clinical trial","volume":"5","author":"Mirsadraee","year":"2019","journal-title":"Curr Med Mycol"},{"key":"2024061323543871400_ciad607-B34","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024061323543871400_ciad607-B35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1399-3062.2006.00125.x","article-title":"Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Alexander","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"2024061323543871400_ciad607-B36","doi-asserted-by":"crossref","first-page":"e13200","DOI":"10.1111\/tid.13200","article-title":"Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections","volume":"22","author":"Farges","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"2024061323543871400_ciad607-B37","doi-asserted-by":"crossref","first-page":"e12898","DOI":"10.1111\/tid.12898","article-title":"Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss transplant cohort study","volume":"20","author":"Neofytos","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2024061323543871400_ciad607-B38","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.healun.2018.06.008","article-title":"Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study","volume":"37","author":"Aguilar","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2024061323543871400_ciad607-B39","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/ajt.12691","article-title":"Epidemiology of invasive mold infections in lung transplant recipients","volume":"14","author":"Doligalski","year":"2014","journal-title":"Am J Transplant"},{"key":"2024061323543871400_ciad607-B40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation\u2013a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"2024061323543871400_ciad607-B41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-3062.2006.00156.x","article-title":"Variation in antifungal prophylaxis strategies in lung transplantation","volume":"8","author":"Husain","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"2024061323543871400_ciad607-B42","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.healun.2003.09.028","article-title":"A survey of anti-fungal management in lung transplantation","volume":"23","author":"Dummer","year":"2004","journal-title":"J Heart Lung Transplant"},{"key":"2024061323543871400_ciad607-B43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1378\/chest.123.3.800","article-title":"Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients","volume":"123","author":"Helmi","year":"2003","journal-title":"Chest"},{"key":"2024061323543871400_ciad607-B44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1378\/chest.114.5.1321","article-title":"Pulmonary aspergillosis in cystic fibrosis lung transplant recipients","volume":"114","author":"Nunley","year":"1998","journal-title":"Chest"},{"key":"2024061323543871400_ciad607-B45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 Years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl Int"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad607\/52550872\/ciad607.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/6\/1564\/58211921\/ciad607.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/78\/6\/1564\/58211921\/ciad607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T13:42:16Z","timestamp":1718372536000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/78\/6\/1564\/7295833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2024,6,14]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad607","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,15]]},"published":{"date-parts":[[2023,10,6]]}}}